Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors

Clinical Cancer Research

Volumn 21, Issue 5, 2015, Pages 1002-1009

  Goldman, Jonathan ^a   Eckhardt, S Gail ^b   Borad, Mitesh J ^c   Curtis, Kelly K ^c   Hidalgo, Manuel ^d   Calvo, Emiliano ^d   Ryan, David P ^e   Wirth, Lori J ^e   Parikh, Asit ^f   Partyka, James ^f   Faessel, Helene ^f   Gangolli, Esha ^f   Stewart, Sally ^a   Rosen, Lee S ^a   Bowles, Daniel W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

^d START   (Spain)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 ETHYL 4,5 DIHYDRO N [1 (HYDROXYACETYL) 4 PIPERIDINYL] 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) 3 (2,2,2 TRIFLUOROETHOXY) 1H PYRROLO[3,2 C]PYRIDINE 2 CARBOXAMIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SONIC HEDGEHOG PROTEIN; ANTINEOPLASTIC AGENT; GLI1 PROTEIN, HUMAN; MESSENGER RNA; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; TAK-441; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GLI1;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BLEEDING; CELL PROLIFERATION; CELL SURVIVAL; CHILL; CLINICAL ARTICLE; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DECREASED APPETITE; DIARRHEA; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GENE; GENE EXPRESSION REGULATION; GLI1 GENE; HEADACHE; HEPATOBILIARY DISEASE; HUMAN; HUMAN TISSUE; HYPONATREMIA; INFECTION; LIVER FAILURE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PAIN; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; SIGNAL TRANSDUCTION; SKIN BIOPSY; SOLID TUMOR; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASMS; ORAL DRUG ADMINISTRATION; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS; PYRIDINES; PYRROLES; RETREATMENT; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; ZINC FINGER PROTEIN GLI1;

EID: 84928794048     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1234     Document Type: Article

References (30)

1. Zeng X, Goetz JA, Suber LM, Scott WJ Jr, Schreiner CM, Robbins DJ. A freely diffusible form of Sonic hedgehog mediates long-range signalling. Nature 2001;411:716-20.
2. Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, et al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 1996;384:129-34.
3. Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009;106: 4254-9.
4. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297:1559-61.
5. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743-54.
6. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996;14:78-81.
7. Wolter M, Reifenberger J, Sommer C, Ruzicka T, Reifenberger G.Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997; 57:2581-5.
8. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997;57:842-5.
9. Bridge JA, Liu J, Weibolt V, Baker KS, Perry D, Kruger R, et al. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: an intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 2000; 27:337-44.
10. Ok CY, Singh RR, Vega F. Aberrant activation of the hedgehog signaling pathway in malignant hematological neoplasms. Am J Pathol 2012;180: 2-11.
11. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res 2009;69:6007-10.
12. Galimberti F, Busch AM, Chinyengetere F, Ma T, Sekula D, Memoli VA, et al. Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1mutations. Int J Oncol 2012;41: 1751-61.
13. Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010;28:5321-6.
14. McMillan R, Matsui W. Molecular pathways: the hedgehog signaling pathway in cancer. Clin Cancer Res 2012;18:4883-8.
15. Ohashi T, Oguro Y, Tanaka T, Shiokawa Z, Tanaka Y, Shibata S, et al. Discovery of the investigational drug TAK-441, a pyrrolo[3, 2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. BioorgMed Chem 2012;20:5507-17.
16. Tojo H, Shibata S, Satoh Y, Kawamura M, Inazuka M, Yamakawa H, et al. TAK-441, a novel investigational small molecule hedgehog pathway inhibitor for use in cancer therapy. Cancer Res 2011;71(suppl): Abstr 2823.
17. Kogame A, Tagawa Y, Shibata S, Tojo H, Miyamoto M, Tohyama K, et al. Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice. Drug Metab Dispos 2013;41:727-34.
18. Ibuki N, Ghaffari M, Pandey M, Iu I, Fazli L, Kashiwagi M, et al. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer 2013;133:1955-66.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
20. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. NEngl J Med 2012;366:2171-9.
21. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:2502-11.
22. Jimeno A, Weiss GJ, MillerWHJr, Gettinger S, Eigl BJ, Chang AL, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 2013;19:2766-74.
23. Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011;17: 2512-20.
24. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
25. Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, et al. Hedgehog signaling alters reliance on EGF receptor signaling andmediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res 2013;73:3381-92.
26. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012;21:374-87.
27. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013;19:1410-22.
28. Xie J, Bartels CM, Barton SW, Gu D. Targeting hedgehog signaling in cancer: research and clinical developments. Onco Targets Ther 2013;6:1425-35.
29. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition ofHedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
30. Infinity Pharmaceuticals. Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer. 2012 press release [Accessed 03 March 2014 ]. Available from: http://phx. corporate-ir.net/phoenix.zhtml?c=121941&p=irol-newsArticle&ID= 1653550&highlight=.